This is a multicenter, randomized, double-blind, sham-controlled trial, to determine the efficacy and safety of cTBS in treating patients with acute ischemic stroke after endovascular treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
60
The patients will be treated with cTBS and usual medical treatment after endovascular treatment
The patients will be treated with sham-cTBS and usual medical treatment after endovascular treatment
Xijing Hospital
Xi'an, Shaanxi, China
RECRUITINGChanges of infarct volumes from baseline to Day 5
Time frame: 5 days after enrollment
Death
Time frame: The first 5 days after enrollment
NIHSS at Day 5
Time frame: 5 days after enrollment
Early neurological deterioration
proportion of patients with an increase of ≥4 points in NIHSS at 3 days
Time frame: 3 days after enrollment
Final infarct volume
The infarct volume on DWI at 5 days
Time frame: 5 days after enrollment
Intracranial hemorrhage incidence
Time frame: 24h after enrollment
Proportion of patients with symptomatic intracranial hemorrhage
Time frame: 90 days after enrollment
Proportion of patients with mRS 0-2
Time frame: 90 days after enrollment
Barthel Index score
Time frame: 90 days after enrollment
Stroke recurrence
Time frame: 90 days after enrollment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.